Abstract:BACKGROUND-AIMPharmacogenetics is a discipline oriented to the study of the genetic basis of interindividual differences in the response to drugs, both at the level of efficacy and safety.One of the most widely used applications of Pharmacogenetics in clinical practice is the genetic test for HLA-B*5701 in patients who are going to start treatment with abacavir, due to its relationship with the hypersensitivity reaction it produces.Other adverse reactions of this type are: Relationship HLA-B15.02 with Steven-Johnson Syndrome and toxic epidermal necrolysis by carbamazepine, relationship HLA-B58.01 with Hypersensitivity Syndrome, Steven Johnson Syndrome and toxic epidermal necrolysis by allopurinol, relationship HLA-B35 with skin eruption by nevirapine and relationship HLA-B13.01 with hypersensitivity reaction induced by dapsone (DIHR).The objective of the study is to determine the prevalence of the HLA-B57.01 allele and the HLA-B35.05,HLA-B58.01,HLA-B15.02 and HLA-B13.01 alleles associated with adverse drug reactions in our healthcare area. METHODSDescriptive observational study of patients with HIV diagnosis, with request for genotyping HLA-B57.01 in our hospital area between July 2016 and September 2019 They were a total of 613 patients.Maxwell® 16 System, Blood DNA Purification System, was used to isolate the DNA in an automated way, which was later amplified by PCR.A strip probe assay, INNO-LiPAHLA-B Update Plus, was then used to determine the molecular typing of human leukocyte antigen (HLA) B alleles.The results were analyzed using Excel. RESULTSTo determine the prevalence of HLA-B alleles, an Excel database was created with a total of 613 samples.A prevalence of 3.75% was found for the HLA B57.01 allele.The prevalences of the other alleles with their respective confidence intervals (IC95%) and number of patients are detailed below: HLA-B 57.01 3,75% (2,51-5,57) 23 patients, HLA-B 58 0,82% (0,35-1,89) 5 patients, HLA-B35 9,79% (7,68-12,40) 60 patients, HLA-B15 1,14% (0,55-2,34) 7 patients and HLA-B13 1,63% (0,89-2,98) 10 patients. CONCLUSIONSThe calculated prevalences are lower than those described by other studies, such as the PREDICT-1 study with the participation of 15 European countries.We also found a high prevalence of the HLA-B35 allele, associated with adverse reactions to Nevirapine, more particularly the skin eruption induced by this second line antiretroviral in Spain.This high prevalence of HLA-B alleles associated with drug intolerance in our HIV population suggests that the determination of these alleles may be of great importance and utility in routine clinical practice in the at-risk population.

Erratum To: Studies on Abacavir-Induced Hypersensitivity Reaction: a Successful Example of Translation of Pharmacogenetics to Personalized Medicine

Associations Between Human Leukocyte Antigen Polymorphisms and Hypersensitivity to Antiretroviral Therapy in Patients with Human Immunodeficiency Virus: a Meta-Analysis.

Toxicology, Including Therapeutic Drug Monitoring

[Importance of HLA in Determining Individual Differences in the Onset of Adverse Drug Reactions]

Drug hypersensitivity caused by alteration of the MHC-presented self-peptide repertoire

[Pharmacogenetic research in the association between human leukocyte antigen and adverse drug reactions].

Direct PCR: a new pharmacogenetic approach for the inexpensive testing of HLA-B*57:01

Abcb1 Variation And Treatment Response In Aids Patients: Initial Results Of The Henan Cohort

An Animal Model of Abacavir-Induced HLA-Mediated Liver Injury.

Rapid and Reliable Genotyping Ofhla-B*57:01In Four Chinese Populations Using a Single-Tube Duplex Real-Time Polymerase Chain Reaction Assay

The VHSE-based classifications of the peptide ligands of HLA-B~5701 and HLA-B~5801

Progress in Study on the Association Between HLA Genetic Variation and Adverse Drug Reactions.

Update on HLA-B*15:02 allele associated with adverse drug reactions

The utility of surrogate markers in predicting HLA alleles associated with adverse drug reactions in Vietnamese

[The Associations Between Idiosyncratic Adverse Drug Reactions and HLA Alleles and Their Underlying Mechanism].

[Host's genetics in HIV disease]

Brief Report: Should Abacavir Be a First-Line Alternative for Adults With HIV in Sub-Saharan Africa?

Effect of CYP2B6 Gene Polymorphisms on Efavirenz Plasma Concentrations in Chinese Patients with HIV Infection

Peptide Binding Specificities of Hla-B5701 and B5801

The PD1 inhibitory pathway and mature dendritic cells contribute to abacavir hypersensitivity in human leukocyte antigen transgenic PD1 knockout mice

Association between polymorphisms and interferon/ribavirin treatment response in hepatitis C virus type 1 infection in Chinese population: a prospective study.